AIM ImmunoTech (NYSE:AIM) Price Target Cut to $1.00

AIM ImmunoTech (NYSE:AIM) had its price target reduced by stock analysts at Maxim Group from $2.00 to $1.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target would suggest a potential upside of 284.76% from the stock’s current price.

Separately, Ascendiant Capital Markets reduced their target price on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

AIM ImmunoTech Stock Down 3.4 %

Shares of AIM opened at $0.26 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.17 and a current ratio of 1.17. AIM ImmunoTech has a 52 week low of $0.21 and a 52 week high of $0.62. The stock has a market capitalization of $13.38 million, a price-to-earnings ratio of -0.41 and a beta of -0.39. The stock has a fifty day moving average of $0.30 and a 200-day moving average of $0.36.

AIM ImmunoTech (NYSE:AIM) last posted its earnings results on Wednesday, August 14th. The company reported ($0.03) EPS for the quarter. AIM ImmunoTech had a negative net margin of 13,952.74% and a negative return on equity of 269.04%. The firm had revenue of $0.05 million during the quarter. As a group, sell-side analysts anticipate that AIM ImmunoTech will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC purchased a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).